Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for Rani Therapeutics in a research note issued on Monday, July 10th. Cantor Fitzgerald analyst O. Brayer expects that the company will earn ($1.58) per share for the year. Cantor Fitzgerald has a 'Overweight' rating on the stock. The consensus estimate for Rani Therapeutics' current full-year earnings is ($1.44) per share. Get Rani Therapeutics alerts: Several other brokerages have also issued reports on RANI.

https://www.dailypolitical.com/2023/07/14/research-analysts-offer-predictions-for-rani-therapeutics-holdings-inc-s-fy2023-earnings-nasdaqrani.html

#dailypolitical